#Israel #medical technology #investor events #Yokneam #InMode

InMode's Upcoming Investor Engagements

InMode Ltd., a prominent name in the field of innovative medical technologies, is set to make significant appearances at essential investor conferences in the coming weeks. This initiative emphasizes InMode's commitment to transparency and active communication with its stakeholders.

Barclays Virtual West Coast Bus Trip

The first event, the Barclays Virtual West Coast Bus Trip, will feature key presentations by the outgoing Chief Financial Officer, Yair Malca, alongside Moshik Itzkovich, Senior Vice President of Finance. Scheduled for May 20, this virtual format seeks to engage investors in a comprehensive dialogue about the company's strategic direction and operational successes.

Jefferies Global Healthcare Conference

Adding to the excitement, InMode will also participate in the highly anticipated Jefferies Global Healthcare Conference. On June 3, Malca and Itzkovich will participate in an in-person fireside chat, moderated by Senior Equity Analyst Matt Taylor. This session promises to delve deeper into InMode's innovative approaches and future prospects, showcasing their leadership in the med-tech space. Attendees will have the opportunity to attend one-on-one meetings, fostering deeper investor relations and insights.

A live webcast of these presentations will be readily available for those unable to attend in person, ensuring broader access and engagement from the investment community. This accessibility aligns with InMode's goal of promoting broader understanding and confidence in its operations and growth strategies.

Innovation at InMode

InMode specializes in developing, manufacturing, and marketing medical devices that utilize cutting-edge radiofrequency (RF) technology. Their products are designed not only to introduce new surgical techniques but also to enhance existing treatment modalities across various medical fields including plastic surgery, gynecology, dermatology, otolaryngology, and ophthalmology. By leveraging minimally invasive RF technologies, InMode has created an extensive range of high-quality products that have revolutionized medical procedures.

The company's continuous efforts to innovate highlight its commitment to patient care and operational excellence. As such, discussions during the conferences will likely focus on how InMode intends to expand its market presence and address evolving healthcare needs through technology.

For additional details about InMode's participation at these investor events, or insights into their latest innovations and financial performance, stakeholders are encouraged to visit the official InMode website: www.inmodemd.com.

Conclusion

In summary, InMode's active participation in these upcoming investor conferences underscores a strategic approach to maintain open channels with investors, share valuable insights about its innovations, and present the company's future growth trajectories. As a key player in medical technology, InMode continues to solidify its position through dedicated engagement and transformative product offerings.